10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2020 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2020 10-K (Filed: Feb 19, 2021) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2020 | Dec 31, 2019 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $ 6,838 | 3,860 |
| Investments, primarily bank time deposits and U.S. treasury bills | 310 | 280 |
| Trade receivables, less allowances of - 2020: $460; 2019: $384 | 6,414 | 5,425 |
| Inventories: | ||
| Finished products | 3,030 | 2,784 |
| Work in process | 712 | 560 |
| Materials | 1,270 | 972 |
| Total inventories | 5,012 | 4,316 |
| Other prepaid expenses and receivables | 1,867 | 1,786 |
| Total current assets | 20,441 | 15,667 |
| Investments | 821 | 883 |
| Property and equipment, at cost: | ||
| Land | 538 | 519 |
| Buildings | 4,014 | 3,702 |
| Equipment | 12,884 | 11,468 |
| Construction in progress | 1,357 | 1,110 |
| Property and equipment, at cost | 18,793 | 16,799 |
| Less: accumulated depreciation and amortization | 9,764 | 8,761 |
| Net property and equipment | 9,029 | 8,038 |
| Intangible assets, net of amortization | 14,784 | 17,025 |
| Goodwill | 23,744 | 23,195 |
| Deferred income taxes and other assets | 3,729 | 3,079 |
| Total Assets | 72,548 | 67,887 |
| Liabilities and Shareholders' Investment | ||
| Current liabilities: | ||
| Short-term borrowings | 213 | 201 |
| Trade accounts payable | 3,946 | 3,252 |
| Salaries, wages and commissions | 1,416 | 1,237 |
| Other accrued liabilities | 5,165 | 4,035 |
| Dividends payable | 798 | 635 |
| Income taxes payable | 362 | 226 |
| Current portion of long-term debt | 7 | 1,277 |
| Total current liabilities | 11,907 | 10,863 |
| Long-term debt | 18,527 | 16,661 |
| Post-employment obligations and other long-term liabilities | 9,111 | 9,062 |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2020: 1,981,156,896; 2019: 1,976,855,085 | 24,145 | 23,853 |
| Common shares held in treasury, at cost - Shares: 2020: 209,926,622; 2019: 214,351,838 | (10,042) | (10,147) |
| Earnings employed in the business | 27,627 | 25,847 |
| Accumulated other comprehensive income (loss) | (8,946) | (8,465) |
| Total Abbott Shareholders' Investment | 32,784 | 31,088 |
| Noncontrolling interests in subsidiaries | 219 | 213 |
| Total Shareholders' Investment | 33,003 | 31,301 |
| Total Liabilities and Shareholders' Investment | 72,548 | 67,887 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |